By Marie Rosenthal, MS
The FDA approved omadacycline (Nuzyra, Paratek) to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs), the first once-daily IV and oral antibiotic approved to treat both types of patients in nearly 20 years.